)
Aclaris Therapeutics (ACRS) investor relations material
Aclaris Therapeutics Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Pipeline updates and priorities
Bosakitug, a TSLP monoclonal antibody, missed the atopic dermatitis endpoint; the small study showed robust Th1, Th17 and Th2 pharmacodynamic responses, while single-agent TSLP was not part of the base plan.
Modzatinib 2138’s oral lichen planus study started last week and will cover mucosal, cutaneous and scalp phenotypes.
The 9494 next-generation ITK program completed required toxicology; filing is planned in the coming weeks, followed by SAD/MAD studies and proof of concept in 2027.
9494 is being developed for TH2-based oral indications, potentially atopic disease or asthma; disease-related measures such as elevated FeNO may be included in MAD work.
A second indication for the 052 bispecific, either asthma or atopic dermatitis, is expected to be selected before year-end; designs may include a positive control or Dupixent failures.
052 bispecific and EoE strategy
EoE is now the lead indication for 052; tezepelumab’s positive data increased the rationale for a larger study focused initially on EoE.
KOLs cited rising EoE prevalence, potentially exceeding 1 million patients, and TSLP’s potential to address broader inflammatory pathways beyond eosinophils.
The EoE study is expected in 2027, with histologic, symptom and endoscopic outcomes; the aim is an efficient design that moves rapidly from phase 2 toward registration.
Target profile includes faster onset and greater depth or breadth of response; management also anticipates evaluating induction and maintenance approaches and longer dosing intervals.
Oral lichen planus study
The 2138 basket study starts with oral disease, then plans cutaneous and scalp cohorts; target enrollment is 35–40 patients, with interim analysis after ~60% reach week 16.
ODSS is the primary endpoint; IGA and patient-reported outcomes are also included. ODSS is a continuous 0–106 measure and was used to power the initial cohort.
After interim results, the plan is to consult the FDA on the registrational program; Fast Track designation enables further agency interaction.
Management cited ITK’s upstream mechanistic fit with T-cell receptor-driven disease and viewed an ODSS response near 50% as compelling.
A recent topical corticosteroid study in milder oral disease showed a 20% response rate; management noted the different disease severity and lower baseline ODSS scores.
- Positive ATI-052 data and October financing support an expected cash runway through H1 2029.ACRS
Q3 2026 - ATI-052 showed AD and asthma activity; next-stage development will prioritize EoE.ACRS
Study result - Multiple late-stage readouts and new trials in I&I set the stage for significant pipeline progress.ACRS
12th Annual Cantor Fitzgerald Global Healthcare Conference - Net loss rose to $41.3M as R&D spending increased, with $170.6M liquidity and major clinical milestones ahead.ACRS
Q2 2026 - Advancing TSLP biologics and ITK/JAK3 inhibitors with late 2026 clinical catalysts expected.ACRS
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Key bispecific and TSLP mAb data readouts expected in H2, with phase II asthma trial starting Q4.ACRS
Jefferies Global Healthcare Conference 2026 - All proposals passed, with board elections, compensation, and auditor ratification approved.ACRS
AGM 2026 - Multiple late-stage immunology assets advance toward key 2024 and 2026 milestones, backed by strong funding.ACRS
Bank of America Global Healthcare Conference 2026 - Lead assets show strong efficacy and safety in large immune disease markets, with cash runway to 2028.ACRS
Corporate presentation
)
)
)
)
)
)
)
)